IL290250A - Targeted gene therapy to treat neurological diseases - Google Patents

Targeted gene therapy to treat neurological diseases

Info

Publication number
IL290250A
IL290250A IL290250A IL29025022A IL290250A IL 290250 A IL290250 A IL 290250A IL 290250 A IL290250 A IL 290250A IL 29025022 A IL29025022 A IL 29025022A IL 290250 A IL290250 A IL 290250A
Authority
IL
Israel
Prior art keywords
gene therapy
neurological diseases
targeted gene
treat neurological
treat
Prior art date
Application number
IL290250A
Other languages
Hebrew (he)
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of IL290250A publication Critical patent/IL290250A/en

Links

IL290250A 2019-08-01 2022-01-31 Targeted gene therapy to treat neurological diseases IL290250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881540P 2019-08-01 2019-08-01
PCT/US2020/044598 WO2021022208A1 (en) 2019-08-01 2020-07-31 Targeted gene therapy to treat neurological diseases

Publications (1)

Publication Number Publication Date
IL290250A true IL290250A (en) 2022-04-01

Family

ID=72145498

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290250A IL290250A (en) 2019-08-01 2022-01-31 Targeted gene therapy to treat neurological diseases

Country Status (3)

Country Link
EP (1) EP4007609A1 (en)
IL (1) IL290250A (en)
WO (1) WO2021022208A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148192A1 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Chimeric aav and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
FR2814642B1 (en) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
MA44546B1 (en) * 2016-06-15 2021-03-31 Univ California Variant adeno-associated viruses and methods of use
US20200054711A1 (en) * 2017-02-28 2020-02-20 The Penn State Research Foundation Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow

Also Published As

Publication number Publication date
WO2021022208A1 (en) 2021-02-04
EP4007609A1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
HK1246712A1 (en) Nerve stimulation for treatment of diseases and disorders
IL288574A (en) Oligonucleotides and methods of use for treating neurological diseases
IL284554A (en) Gene therapy constructs for treating wilson disease
EP3364970A4 (en) Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
IL279918A (en) Gene therapy vectors for treatment of danon disease
ZA201903003B (en) Treatment of neurological diseases
IL285238A (en) Gene therapy vectors for treatment of danon disease
HK1253299A1 (en) Improved methods for treating ocular diseases by gene therapy
EP4055033A4 (en) Combination therapy to treat brain cancer
SG11202101819QA (en) Gene therapy for the treatment of galactosemia
GB202114972D0 (en) Gene therapy
EP3413898A4 (en) Use of trehalose for treatment of neurological diseases
GB201914034D0 (en) Treatment of neurological disorders
GB202003618D0 (en) Gene Therapy
IL290250A (en) Targeted gene therapy to treat neurological diseases
IL282360A (en) Treatment of neurological diseases
IL284411A (en) Targeted delivery of therapeutic molecules
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
EP4247958A4 (en) Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases
GB202005321D0 (en) Gene therapy treatment
EP3952856A4 (en) Genetic variants associated with response to treatment of neurological disorders
GB201706662D0 (en) Treatment of neurological diseases
IL310018A (en) Kcnv2 gene therapy
IL310017A (en) Retgc gene therapy